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Abstract:  The synthesis of pharmaceuticals and catalysts more and more relies on 
enantiopure chiral building blocks. These can be produced in an environmentally benign 
and efficient way via bioreduction of prochiral ketones catalyzed by dehydrogenases. A 
productive source of these biocatalysts is the yeast Saccharomyces cerevisiae, whose 
genome also encodes a reductase catalyzing the sequential reduction of the γ-diketone  
2,5-hexanedione furnishing the diol (2S,5S)-hexanediol and the γ-hydroxyketone (5S)-
hydroxy-2-hexanone in high enantio- as well as diastereoselectivity (ee and de >99.5%). 
This enzyme prefers NADPH as the hydrogen donating cofactor. As NADH is more stable 
and cheaper than NADPH it would be more effective if NADH could be used in cell-free 
bioreduction systems. To achieve this, the cofactor binding site of the dehydrogenase was 
altered by site-directed mutagenesis. The results show that the rational approach based on a 
homology model of the enzyme allowed us to generate a mutant enzyme having a relaxed 
cofactor preference and thus is able to use both NADPH and NADH. Results obtained from 
other mutants are discussed and point towards the limits of rationally designed mutants. 
Keywords: biocatalysis; 2,5-hexanedione; S. cerevisiae; site-directed-mutagenesis; Gre2p; 
cofactor preference 
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1. Introduction 
Enantiopure chiral alcohols and especially those with more than one functional group or 
stereocenter are of increasing importance as building blocks for the synthesis of chiral 
pharmaceuticals, flavors and agrochemicals, as well as homogeneous catalysts [1-3]. A representative 
example among the multitude of chiral alcohols is the diol (2S,5S)-hexanediol ((2S,5S)-1). It is a key 
building block in the synthesis of chiral ligands used in phospholane based, homogeneous transition 
metal catalysts like (R,R)-Me-DuPhos-Rh which have proven useful in a number of asymmetric 
hydrogenation reactions [3-5]. Furthermore the chiral diol (2S,5S)-1 is also of use in the synthesis of a 
variety of chiral pharmaceutical intermediates, agrochemicals and chiral auxiliaries [3,6-9].  
In order to satisfy the demand for this chiral building block an efficient synthetic route yielding 
enantiopure (2S,5S)-1 is needed. Although numerous synthetic strategies have been developed in the 
past including asymmetric hydrogenation with Ru-BINAP [10], multistep syntheses [4,11,12] and 
enzymatic resolution of racemates [13,14], the most efficient strategy is direct reduction of prochiral 
2,5-hexanedione (3) mediated by dehydrogenases and microorganisms harboring these enzymes, 
respectively. Biocatalytic reduction of ketones to obtain chiral alcohols is not only efficient in terms of 
atom economy [15] but also highly selective and environmentally friendly, as it operates under mild 
reaction conditions [16,17].  
Scheme 1. Reduction of 2,5-hexanedione (3) is stereospecifically catalyzed by Gre2p, 
yielding the chiral building blocks (5S)-hydroxy-2-hexanone ((5S)-2) and (2S,5S)-
hexanediol ((2S,5S)-1) in a consecutive reaction. 
 
 
The first biocatalyst reported of being capable of stereoselectively reducing 2,5-hexanedione was 
the baker’s yeast S. cerevisiae [18]. Although two other biocatalysts, catalyzing the same reaction with 
comparable stereospecificity, namely the dehydrogenases ADH-T from Thermoanaerobacter sp. [19] 
and ADH-A from Rhodococcus ruber [20],  have been reported since then, the dehydrogenase 
responsible for 2,5-hexanedione reduction in S. cerevisiae was identified only recently as the gene 
product of GRE2 [21]. The latter enzyme - designated Gre2p - is especially interesting when it comes 
to the production of the monohydroxyketone (5S)-hydroxy-2-hexanone ((5S)-2) which is, just like 
(2S,5S)-1, a valuable chiral building block [22]. However (5S)-2 is far more difficult to obtain than 
(2S,5S)-1, thus it is of significance that it arises as the intermediate in the consecutive (S)-selective 
reduction of 3 (Scheme 1) [23]. This intermediate transiently accumulates to up to 90% the amount of 
starting material when Gre2p is used as a catalyst, whereas usage of ADH-T and ADH-A, respectively Int. J. Mol. Sci. 2010, 11                 
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yields lower amounts [23,24]. Hence the use of Gre2p is advantageous for the efficient production of 
enantiopure (5S)-2.  
But the use of Gre2p as a biocatalyst is not restricted to reduction of 3. The enzyme rather accepts a 
broad range of substrates including aliphatic and aromatic ketones, chloroketones, diketones as well as 
-ketoesters which are reduced with high stereoselectivity [21,25-32]. The ability of Gre2p to accept 
several substrates is also reflected in studies dealing with its physiological role in S. cerevisiae, in 
which the enzyme is discussed to play a role in the catabolism and metabolism of quite different 
molecules such as ergosterol [33], isovaleraldehyde [34] and methylglyoxal [35].  
It is this broad substrate range which makes Gre2p a highly valuable enzyme in biocatalysis. 
However if Gre2p is to be used for bioreductions in vitro additional care has to be taken for cofactor 
regeneration. Thereby it has to be noted that Gre2p as well as ADH-T and ADH-A prefer NADPH as a 
cofactor, which is compared to its alternative -NADH- less stable [36] and three times more expensive 
(according to the 2009 Sigma-Aldrich Catalogue). Hence in terms of biocatalysis a Gre2p variant 
preferring NADH would be more desirable. 
In order to switch cofactor preference of an enzyme, mutagenesis is the method of choice. 
Especially site-directed mutagenesis has proven useful to alter the cofactor preference of a given 
dehydrogenase [37-41], in which context it has been reported that in some cases changing even one 
sole amino acid is sufficient to invert cofactor preference [41-44]. The latter was also achieved for 
enzymes which are grouped together with Gre2p into the family of short-chain 
dehydrogenases/reductase (SDR) [38,45-48]. Thus it can reasonably be assumed that an NADH-
preferring variant of Gre2p should also be generable by just changing one amino acid. This is in 
accordance with the literature in which it is reported that within the SDR-family cofactor preference is 
thought to be determined by one amino acid [49]. Thus we were encouraged to design and generate a 
tailored Gre2p mutant, which preferably uses NADH as the cofactor of choice through exchanging just 
one amino acid by rationally guided site-directed mutagenesis. In the case of success this rational 
approach based on fundamental knowledge of enzyme architecture in SDRs would be much more 
efficient than generating tailored enzymes through “directed evolution”, which relies on labor 
intensive screening of a huge number of mutants [50]. However it has to be stated that in most cases 
knowledge on enzyme-activity-relationships is still too limited to rationally design a mutant having the 
expected properties which in turn renders “directed evolution” a technique yielding the expected 
results often faster than rational approaches. Nevertheless it should be the aim to gain so much 
understanding of enzyme architecture that rational creation of an effective and selective enzyme 
becomes possible. The results of this work contribute to the knowledge on enzyme-activity-relationships 
in SDRs and thus may take us a bit further to the ultimate goal of rationally designed enzymes. 
2. Results and Discussion 
In order to design a tailored enzyme insights into its structure are a prerequisite. Since a structural 
model based on X-ray crystallography does not yet exist for Gre2p, a structural model (homology 
model) based on a homologous dehydrogenase with known crystal structure needed to be constructed.  Int. J. Mol. Sci. 2010, 11                 
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2.1. Homology Modeling of Gre2p 
Within the protein data bank (PDB; www.rcsb.org) the carbonyl reductase I from Sporobolomyces 
salmonicolor (SSCR; PDB-Code: 1Y1P) shares the highest sequence identity (29%) and similarity 
(18%) with Gre2p and thus serves as the models template (E-value = 3e
-22; 96% of Gre2p aligned). On 
the basis of a global sequence alignment between Gre2p and SSCR (Figure 1) it is now possible to 
assign the secondary and tertiary structure taken from the template SSCR to the primary structure of 
Gre2p, thus constructing the desired homology model. 
Figure 1. Amino acid sequence alignment of the S. cerevisiae dehydrogenase Gre2p 
(GRE2P) with Sporobolomyces salmonicolor carbonyl reductase (SSCR) upon which the 
Gre2p homology model was built. The secondary structure is also given (sec.struc), in 
which B/b indicates -sheets and A/a -helices. The last line indicates whether an amino 
acid is conserved between SSCR and Gre2p by using standard symbols.  
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According to the overall sequence identity between model and template the quality and reliability of 
the model is in the so called “twilight zone”, in which false-positive results increase if a secondary 
structure is deduced from a sequence alignment [51,52]. 
Although the model may not reliably reflect the whole structure of Gre2p in detail, it will reliably 
reflect sub-parts of the enzyme, sharing a higher pair-wise sequence identity and similarity, with SSCR 
than the whole enzyme does. The latter is especially true for the N-terminal part of Gre2p which shares 
44% identity and 18% similarity with SSCR on the sequence level.  
Besides local sequence alignments, the local quality of a homology model can also be described 
through scoring functions such as ProQres [53] or QMEAN [54] (Figure 2). Both algorithms indicate 
that the homology model of Gre2p reliably describes its N-terminus. This is of outstanding importance 
since the N-terminal part of Gre2p, SSCR and other short-chain-dehydrogenases, is responsible for 
binding and recognizing the nicotinamide cofactor via the so called Rossmann-fold [55-57], which is 
exactly the target region to be altered by mutagenesis.  
Figure 2. Predicted deviation of every amino acid residue in the Gre2p homology model as 
assessed by the QMEAN scoring function. QMEAN returns the estimated error of the 
space coordinates per amino acid residue in Ångström. More reliable regions are 
characterized by a residue error below 1 Å, whereas potentially unreliable regions have an 
error of >3.5 Å. It is evident from the figure that the N-terminal region (residues 0-50) of 
the modeled protein structure can be assessed to be quite reliable since the mean predicted 
deviation in this region is 1.3 Å. 
 
2.2. Structural Basis of Cofactor Specificity in Gre2p 
By placing NADP
+ of 1Y1P into the theoretical structure of Gre2p in silico a first insight into its 
binding could be obtained. Since it is our aim to change the cofactor preference of the enzyme it is 
especially important how the dehydrogenase is able to discriminate between NADH and NADPH. As 
can be seen from Figure 3 Gre2p and SSCR both share a common principle for discriminating NADPH 
from NADH and preferring the former. Just like it was proposed for the binding of NADPH by   Int. J. Mol. Sci. 2010, 11                 
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SSCR [58] Gre2p most probably binds the NADPH 2’-phosphate through electrostatic interactions 
with an arginine and lysine residue (Arg32, Lys36 in Gre2p; Arg44 and Lys48 in SSCR). As such, 
formation of salt bridges between the negatively charged phosphate group and the positively charged 
amino acid side chains stabilizes binding of NADPH, whereas NADH, due to the lack of a negatively 
charged phosphate group at the 2’-position of adenyl ribose, is not able to undergo such a strong 
interaction and hence is not able to bind as tightly as NADPH. 
Figure 3.  (A) Binding of the 2’-phosphate group attached to NADPH’s adenyl ribose 
moiety in SSCR (data from crystal structure PDB-Code: 1Y1P) [42]. (B) This binding 
motif is conserved in Gre2p (data from homology model). 
 
 
Apart from Arg32 and Lys36 there is an additional amino acid, Asn9, which is in close proximity to 
the adenyl ribose 2’-phosphate group and thus may stabilize its binding through hydrogen bonds with 
the 3’-hydroxyl-group and 2’-oxygen atom of the adenyl ribose moiety (Figure 3). 
The described phosphate group binding pattern is consistent with the hypothesis of NADPH binding 
in the family of short-chain-dehydrogenases/reductases (SDR) [49,56,57] to which SSCR and Gre2p 
belong [46,58]. According to this theory, SDRs in general bind cofactors via a Rossmann-fold [55,59] 
in which an amino acid having a basic side chain (in most cases Arg, some cases Lys; Arg32 in Gre2p) 
located in the loop after the second -sheet (23-turn, counted from N-terminus of protein) confers 
preference for NADPH. Alternatively this basic amino acid can also be located in the Rossmann-fold 
specific, so called “glycine rich motif”, in which in most of the cases an amino acid having a 
hydrophilic side chain such as Asn, Gln, Ser, Thr (Asn9 in Gre2p) is found [49,57] (Figure 4). With 
the latter considerations in mind it should be possible to rationally design a Gre2p mutant with altered 
cofactor specificity on the basis of the developed Gre2p homology model. Int. J. Mol. Sci. 2010, 11                 
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Figure 4.  Structural basis of cofactor discrimination in dehydrogenases having a 
Rossmann-fold. Depicted are sections of the NADH preferring 7-hydroxysteroid 
dehydrogenase from E. coli (left, PDB-Code 1AHH) and the carbonyl reductase from 
Sporobolomyces salmonicolor (right; PDB-Code 1Y1P). Possible hydrogen bonds are 
indicated by green lines. 
 
2.3. Design and Experimental Evaluation of Mutants 
As it is reported that cofactor discrimination in SDRs largely depends on whether a basic amino 
acid (Arg, Lys) or an acidic amino acid (Glu, Asp) is found in the 23 loop in the cofactor binding 
Rossmann-fold [49] (Figure 4), it should be possible to interconvert the cofactor preference of a given 
SDR just by changing this one amino acid. In the case of Gre2p this would mean exchanging Arg32 
with Glu and Asp, respectively. The negatively charged side chain of Glu32 and Asp32, respectively 
would then lead to the electrostatic repulsion of the negatively charged adenine ribose 2’-phosphate 
group of NADPH thus constraining its binding. Furthermore the carboxy group of Asp or Glu could 
form two hydrogen bonds with both 2’ and 3’-hydroxy-groups of the adenine ribose of NADH, as such 
resembling the situation in NADH preferring dehydrogenases (1AHH in Figure 4). 
In practical Gre2p variants in which Arg32 was replaced by Glu or Asp indeed showed a markedly 
reduced activity with NADPH as a cofactor (Figure 5), which underlines the importance of Arg32 for 
binding of NADPH. However compared to the wild-type enzyme NADH-dependent activity was also 
reduced, rendering this approach ineffective for generating a Gre2p variant preferring NADH   
over NADPH. 
The loss of activity in short-chain dehydrogenases upon replacement of an arginine analogous to 
Arg32 in Gre2p has also been reported for salutaridine dehydrogenase from Papaver somniferum [60] 
as well as for human 17--hydroxysteroid dehydrogenase, which suggests that there is a common 
reason for this effect. As has been proposed by McKeever et al. [61] arginine can play a dual role. 
Accordingly, Arg32 in Gre2p would not only be able to establish salt bridges or hydrogen bonds with 
the 2’-phosphate group of the cofactors adenine ribose moiety but also stabilizes binding of its adenyl 
moiety through --stacking- and cation--interactions . From this follows that the exchange of Int. J. Mol. Sci. 2010, 11                 
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Arg32 against Glu or Asp will not only lead to electrostatic repulsion of NADPH but also to a weaker 
binding of adenine cofactors in general. 
Figure 5. Impact of mutations in the N-terminal region of Gre2p on its 2,5-hexanedione 
reducing activity. Activities are normalized to the wild-type parent = 100% (control), in 
which the NADPH-dependent 2,5-hexanedione reductase activity [140 U/g (protein)] is 
almost 25 times higher than the NADH-dependent one [6 U/g(protein)]. This value is 
changed to 0.9 in the mutant N9E indicating that this mutant slightly prefers NADH   
over NADPH. 
 
 
Besides that, the negative charge in the side chain of Glu32 and Asp32, respectively seems to 
further weaken binding of NAD(P)H cofactors, since substituting Arg32 against Gly and Leu restores 
some of the enzymes NADPH-dependent activity. This observation furthermore shows that -stacking- 
and cation--interactions between Arg32 and the cofactors adenyl-moiety are not indispensable for 
cofactor binding in Gre2p, although the lack of these interactions remarkably decreases the   
enzymes activity. 
In case of Gre2p Arg32Leu NADPH binding may be facilitated through hydrophobic interactions 
between Leu32 and the cofactor’s adenyl-moiety, whereas glycine at position 32 may increase 
flexibility of this part of the protein and thus could enable Gre2p to adopt a conformation which allows 
for more effectively binding the cofactor. 
Nevertheless the conclusion has to be drawn that Arg32 is essential for cofactor binding in Gre2p 
and other SDRs. As such, substitution of Arg32 in Gre2p and homologous SDRs is not a promising 
approach for generating an NADH-preferring variant of any of these enzymes.  
Furthermore, as Arg32 is conserved in this part of the protein among Gre2p homologs from other 
fungi (Figure 6), the observations made with Gre2p Arg32Gly,Leu,Asp,Glu underline that conserved 
amino acids are most often crucial for enzyme function and activity. Thus their sole substitution 
without changing other parts of an enzyme is likely to result in a mutant enzyme having inferior 
activity, when compared to its wild-type parent. Consequently further mutations only concerned non-Int. J. Mol. Sci. 2010, 11                 
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conserved amino acids. Thus mutation of Lys36 in Gre2p, which is well conserved (Figure 6) and 
assumed to be involved in binding the 2’-phosphate group of NADPH (Figure 3), was not considered 
for mutation. 
But in order to decrease the affinity of the enzyme for NADPH a negative charge in this phosphate 
binding region of Gre2p is a prerequisite. Thus the amino acid upstream of Arg32 (Ala31) was chosen 
as the next target. 
Figure 6.  Multiple sequence alignment of proteins homologous to Gre2p from 
S. cerevisiae (highlighted in grey; red frame). Conserved amino acids are marked with an 
asterisk below the alignment, whereas residues thought to be involved in binding 
NADPH’s 2’-phosphate group are indicated by a dot above the alignment. For a full list 
explaining the abbreviations used see Table 1. 
 
 
Substituting Ala31 is expected to be successful as this yields an enzyme whose sequence resembles 
that of the Drosophila alcohol dehydrogenase, an enzyme which is reported to prefer NADH (1B14_A 
in Figure 7). Introducing an amino acid with an acidic side chain downstream of R32 (S33) is not 
reasonable, since the resulting enzyme would resemble the structure of the NADPH dependent porcine 
carbonyl reductase (1N5D_A in Figure 7) and thus is not likely to exhibit a changed cofactor 
preference. 
Although exchanging amino acids equal to Ala31 in Gre2p successfully changed cofactor 
preference from NADPH to NADH in other SDRs like mouse lung carbonyl reductase [63] and human 
estrogenic 17--hydroxysteroid dehydrogenase [38], no change in cofactor preference could be 
observed in Gre2p when Ala31 was replaced by Asp and Glu, respectively. Instead both enzyme 
variants showed a significant loss of activity regardless of the cofactor used what clearly disqualifies 
substitution of Ala31 as a strategy for altering cofactor preference in Gre2p. Unfortunately this 
suggests that mutagenesis strategies are not transferable unrestrictedly from one enzyme to another 
even if they are homologous and grouped in one family. 
 Int. J. Mol. Sci. 2010, 11                 
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Table 1. Abbreviations used in Figure 6. 
Abbreviation 
Name/putative function of the 
protein 
Source organism 
NCBI GenBank 
Accession number 
Zroux 
AF178079_1 
dehydrogenase 
Zygosaccharomyces rouxii  AAF22287.1 
Pstip  GRE2 methylglyoxal reductase  Pichia stipitis CBS 6054  XP_001384081 
Dhans 
DEHA2A06314p  
hypothetical protein 
Debaryomyces hansenii  CAG84554.2 
Pguil 
PGUG_03246 
hypothetical protein 
Pichia guilliermondii ATCC 6260  XP_001485517.1 
Lelon hypothetical  protein  Lodderomyces elongisporus NRRL YB-4239  XP_001527072.1 
Cglab hypothetical  protein  Candida glabrata  XP_445918.1 
GRE2 
Yol151wp / 3-methyl butanal 
reductase 
Saccharomyces cerevisiae  NP_014490 
Calbi oxidoreductase  Candida albicans SC5314  XP_719286 
Lthrm KLTH0F04026p  Lachancea thermotolerans CBS6340  XP_002554383 
Ygl39 dehydrogenase  YGL039w  Saccharomyces cerevisiae  NP_011476.1 
Cglob 
CHGG_00287 
hypothetical protein 
Chaetomium globosum CBS 148.51  XP_001219508.1 
Ylipo YALI0D07062p  Yarrowia  lipolytica  XP_502514 
Vpoly hypothetical  protein  Vanderwaltozyma polyspora DSM 70294  XP_001642950.1 
Pmarn ketoreductase  Penicillium marneffei ATCC 18224  XP_002151938 
Aclav ketoreductase  Aspergillus clavatus NRRL 1  XP_001275327 
Nfish ketoreductase  Neosartorya fischeri NRRL 181  XP_001260510 
Aderm ketoreductase  Ajellomyces dermatitidis SLH14081  XP_002625096 
Ptrit dihydroflavonol-4-reductase  Pyrenophora tritici-repentis Pt-1C-BFP  XP_001938846 
Aflav  aldehyd reductase II  Aspergillus flavus NRRL3357  EED56897.1 
Aoryz  RIB40 hypothetical protein  Aspergillus oryzae  XP_001817435.1 
SSCR carbonyl  reductase  Sporobolomyces salmonicolor  AAF15999 
Acaps aldehyd  reductase  Ajellomyces capsulatus G186AR  EEH09765.1 
Bfckl 
BC1G_06734 
hypothetical protein 
Botryotinia fuckeliana B05.10  XP_001554946.1 
Ssclr 
SS1G_13307 
hypothetical protein 
Sclerotinia sclerotiorum 1980  XP_001585790.1 
Gzeae 
FG11217.1 
hypothetical protein 
Gibberella zeae PH-1  XP_391393.1 
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Figure 7.  Sequence alignment of NADPH and NADH preferring short-chain 
dehydrogenases / reductases with known crystal structure labeled with its corresponding 
PDB Code. The N-terminal amino-acid-sequence is shown, which is responsible for 
cofactor recognition and binding. NADH preferring SDRs are assigned a dot after their 
respective PDB code (for a full table linking the PDB codes with information on the 
respective enzyme, see Table 2). Arrows are indicating those amino acids in the 23-turn 
which according to [49] determine the cofactor preferred by the enzyme. 
 
Table 2. Abbreviations used in Figure 7. 
PDB-Code  Name of the protein  Source organism  Reference 
1XKQ 
short-chain dehydrogenase / reductase 
with unknown function 
Caenorhabditis elegans [74] 
1XHL  tropinone reductase II  Caenorhabditis elegans  [65] 
2HSD 3,20-hydroxysteroid dehydrogenase  Streptomyces exfoliates  [75] 
1AHH 7  -hydroxysteroid dehydrogenase  Escherichia coli  [76] 
1IPE  tropinone reductase II  Datura stramonium  [77] 
1FK8 3-hydroxysteroid dehydrogenase  Comamonas testosteroni  [78] 
1ZBQ 17--hydroxysteroid dehydrogenase 4  Homo sapiens  [79] 
2GDZ 
15-hydroxyprostaglandin 
dehydrogenase type1 
Homo sapiens  [80] 
1B14 alcohol  dehydrogenase  Drosophila lebanonensis  [81] 
1N5D carbonyl  reductase  Sus scrofa  [64] 
 
One reason for the observed behavior may be the bonding angels (in Ala31’s peptide bond. 
Assumed that both bonding angels in the homology model of Gre2p match the ones in the 
template SSCR (PDB: 1Y1P) and remain unchanged after substitution of Ala31 with Glu or Asp, the 
side chain of the amino acid at position 31 would not point towards the 2’-phosphate group of the 
cofactors adenine ribose moiety but in the opposite direction (Figure 8). Int. J. Mol. Sci. 2010, 11                 
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Figure 8. Possible orientation of Glu31 in the homology model of Gre2p Ala31Glu (B) 
compared to the situation in the crystal structure of SSCR (A). In both dehydrogenases the 
side chain of the amino acid residue upstream of arginine (Ala43 in SSCR; Glu31 in Gre2p 
Ala31Glu) points away from the cofactors ribosyl 2’-phosphate moiety and is thus not 
likely to interact with it. 
 
 
Thus the side chains of neither Glu31 nor Asp31 would be able to adopt a conformation allowing 
interaction of the side chains carboxy group with the 2’- and 3’-hydroxygroup of the cofactor’s adenyl 
ribose moiety. Instead the side chains would affect other parts of the protein yielding an almost 
inactive protein. Regardless of the underlying reasons, whose final clarification would require the 
crystal structure of Gre2p being solved (which is beyond the scope of this contribution) it has to be 
noted that substitution of Ala31 in Gre2p is unsuitable for generating an NADH dependent variant of 
the enzyme. 
Far better results were obtained by exchanging Asn9 by Asp and Glu, respectively. As is depicted 
in Figure 5 substitution of Asn9 with Asp brought about a decrease in the NADPH dependent activity 
while at the same time NADH-dependent 2,5-hexanedione reductase activity increased. This 
difference becomes even more pronounced if the side chain of the amino acid at position 9 is 
prolonged by one carbon atom, i.e., substituting Asp9 with Glu. 
As Asn9 is already able to interact with the 3’-hydroxy and 2’-phosphate group of the cofactors 
adenine ribose moiety in the wild-type enzyme, it is reasonable that changing the properties of this 
amino acids side chain from polar but uncharged (Asn) to charged (Asp, Glu) brings about the 
electrostatic repulsion needed to decrease binding of NADPH and permits formation of hydrogen 
bonds between the 2’- and 3’-ribose hydroxyl groups and the side chain carboxyl group (Figure 9). 
Compared to Gre2p Asn9Asp formation of hydrogen bonds and repulsion of NADPH’s additional 
phosphate group seems to become more pronounced in Gre2p  Asn9Glu (Figure 5). This appears 
reasonable since the side chain of Glu is one carbon atom longer than the one of Asp and thus brings 
the carboxy group of Glu9 in closer proximity to the adenylribosyl 2’- and 3’-hydroxygroups, which 
allows for the establishment of strong hydrogen bonds between Glu9 and the cofactor. Moreover the 
side chain of Glu9 would even hamper binding of NADPH sterically (Figure 9). 
 Int. J. Mol. Sci. 2010, 11                 
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Figure 9. Proposed binding of NADPH in Gre2p wild-type (A) and its mutant variants 
Asn9Asp (B) and Asn9Glu (C). In Gre2p  Asn9Glu NADH dependent 2,5-hexanedione 
reductases activity is increased, since Glu9 is able to form hydrogen bonds (green dotted 
lines) with both of the adenyl ribose hydroxyl groups and constrains binding of NADPH 
through electrostatic interaction as well as steric hindrance (possible collision with the 
phosphate moiety is indicated with a purple dotted line). 
 
 
The change of cofactor preference in Gre2p Asn9Glu is further corroborated by kinetic studies of 
this mutant enzyme. As is shown in Table 3 the mutants apparent Michaelis-constant for NADH is 
decreased by a factor of 1.5 compared to the wild-type parent. Similarly the apparent maximal velocity 
of the 2,5-hexanedione reduction using NADH increased almost 2-fold upon exchange of Asn9 with 
Glu. Thus cofactor preference of Gre2p was changed from strongly preferring NADPH in the wild-
type to quite promiscuous in the N9E mutant which has no pronounced preference NADH and 
NADPH, respectively (Table 3).  
As the enzyme is almost as stable as its wild-type parent (the half-live in 0.1 M phosphate buffer pH 
7.0 at 30 °C was determined to be 24 h for the wild-type and 21 h for the Asn9Glu mutant) it may 
already be used to reduce 2,5-hexandion in vitro using NADH furnishing (5S)-2 and (2S,5S)-1. The 
stereoselectivity of Gre2p [21,23] is unlikely to be altered by the exchange of Asn9 since the substrate 
binding pocket is about 15 Å away from Asn9 and made of amino acids far more downstream.  
Table 3. Apparent kinetic constants determined for Gre2p wild-type (Gre2p wt) and its 
mutant Gre2p Asn9Glu (Gre2p N9E). 
  Gre2p wt   Gre2p N9E 
  NADPH NADH  NADPH  NADH 
KM 
cin mM  0.038  1.45  1.52  0.96 
vmax 
a,c in U/g (protein)  288  81  272  147 
Cofactor preference 
b 136  0,007  1.2  0.9 
a v max is given instead of kcat since the protein was not purified to homogeneity;  
b  cofactor preference can be assessed by dividing the enzymes’ catalytic efficiencies (kcat/KM) 
obtained with NADPH as a cofactor by the one obtained with NADH. As the amount of enzyme 
can be crossed out in the latter formula kcat can be substituted by vmax; values above zero indicate 
preference for this cofactor;  
c  all kinetic constants given are apparent constants since only the amount of the cofactor was 
varied, whereas the concentration of 2,5-hexanedione was kept constant at 10 mM. 
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Hence there is substantial evidence that exchanging Asn9, which is situated within the so called 
“glycine rich motif” of Gre2p, with Asp or Glu improves the enzyme’s ability to use NADH as a 
cofactor. Furthermore this observation appears likely to be not restricted to the single case of Gre2p. 
Since a hydrophilic amino acid residue (namely Asn, Thr, Ser etc.) corresponding to Asn9 in Gre2p, is 
found in many NADPH-dependent SDRs (see Figure 6 and [57]), it can be suggested that exchanging 
Asn9 with Glu and Asp, respectively, will - in most of the cases - result in an improved capability of 
the enzyme to use NADH as a cofactor. From crystal structures of NADPH-dependent SDRs is 
furthermore known that this certain amino acid often adopts a conformation which allows formation of 
hydrogen bonds between this residue and the cofactor’s 2’-and 3’-hydroxy groups attached to the 
adenyl ribose moiety (for a few examples see Figure 10). 
Hence exchanging it with Glu and Asp, respectively will most likely lead to an enzyme in which 
binding of NADH is improved in the same way as is reported for the mutant Gre2p  Asn9Glu 
(Figure 9). 
Figure 10. The amino acid residue corresponding to Asn9 in Gre2p is a promising target 
for alteration of cofactor preference in NADPH-dependent SDRs in general, since this 
amino acid is already forming hydrogen bonds with the 2’-phosphate and 3’-hydroxy 
group of the cofactor’s adenyl ribose moiety. Depicted is the orientation of this certain 
amino acid towards the 2’-phosphate and 3’-hydroxy group attached to the cofactor’s 
adenyl ribose moiety taken from four representative crystal structure of NADPH   
dependent SDRs. 1ND5–carbonyl reductase from Sus scrofa [64]; 1XHL–putative 
tropinone reductase II from Caenorhabditis elegans [65]; 1Y1P–carbonyl reductase from 
Sporobolomyces salmonicolor [58]; 2C29–dihyroflavonol reductase from Vitis 
vinifera [66]. 
1N5D (Asn13) 
 
1XHL (Ser15) 
 
 
1Y1P (Asn21)  2C29 (Ser14) 
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Taken together this study allows concluding that cofactor preference in Gre2p is not only 
determined by the presence of an amino acid with basic or acidic side chain in the loop after the 
2-strand. Apparently preference for NADPH is particularly conferred by the presence of a second 
amino acid with a basic side chain (Arg, Lys) found at least three amino acids downstream of the 
conserved Arg residue (e.g., in the SDR 2C29 Arg37 is separated from Lys44 by six amino acids). 
Thus an inversion of cofactor preference in Gre2p can only be obtained if several amino acids are 
exchanged. For instance it would be of interest whether an effective enzyme preferring NADH can be 
obtained through exchanging the full loop after the sheet 2 with the one found in NADH   
dependent SDRs.  
However a single substitution of one amino acid is sufficient to broaden cofactor acceptance and 
usage. Thus this study has shown that in SDRs amino acids within the conserved GxxG Motif are a 
valuable target for mutations if cofactor preference is to be altered. 
Besides the success of having generated a Gre2p mutant with relaxed cofactor preference it must be 
noted that this mutant enzyme does not reach the ideal of being as catalytically efficient using NADH 
as it is the wild-type using NADPH. As such the mutant enzymes KM(NADH) is still more than  
20 times higher than the KM(NADPH) of the wild-type Gre2p and the ratio 
vmax(NADPH)wt/vmax(NADH)N9E is significantly greater than one, although the ultimate goal would be 
to keep this ratio at a value of one or below. 
Similar observations were also made in previous rational mutagenesis studies aiming for alteration 
of cofactor preference in short-chain dehydrogenases [38,47,48]. For instance Huang et al., inverted 
the cofactor preference of human estrogenic 17--hydroxysteroid dehydrogenase by replacing Leu36 
with Asp (Leu36 corresponds to Ala31 in Gre2p). But also in this case the mutant is not as 
catalytically efficient as the parent (30 times smaller catalytic efficiency), which is also reflected in the 
reported Michaelis-constants. As such the mutants (L36D) KM(NADH) is 17 times bigger than the 
KM(NADPH) of the corresponding wild-type enzyme [38]. 
Thus it appears that although a switch or at least a relaxation in cofactor preference of a short-chain 
dehydrogenase is achievable by merely mutating one single amino acid residue, the resulting enzyme 
will most probably not have the same catalytic efficiency as its wild-type parent. This result is rather 
disadvantageous if the enzyme of choice is to be used in a biotechnological process. Since high space 
time yields (~100 g/L*d) and low biocatalyst loading are clear prerequisites for economically viable 
biotransformations [67], mutagenesis is expected to provide enzymes which exhibit the desired 
properties, with a catalytic efficiency being equal to or preferentially exceeding that of their wild-type 
counterparts. In order to achieve this by rational approaches, far too less is known about enzyme 
architecture and structure activity relationships in whole enzymes. Thus from a current point of view 
methods using random mutagenesis and high-throughput screening appear more promising than 
rational approaches in generating new powerful tailored biocatalysts. However with an increasing 
knowledge in enzyme architecture and structure activity relationship rational design of tailor made 
enzymes appears not only feasible but also much less time-consuming than multiple rounds of 
diversity generation and successive screening. Int. J. Mol. Sci. 2010, 11                 
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3. Experimental Section 
3.1. Chemicals 
Technical grade 2,5-hexanedione was obtained from Wacker Chemie AG (Munich, Germany) and 
purified to >99% by distillation. DNA-modifying enzymes were purchased from Fermentas (St. Leon-
Rot, Germany). 
3.1.1. Strains and Growth Conditions 
Within this study plasmid propagation was carried out with Escherichia coli TOP10 (Invitrogen
TM, 
Calrlsbad, CA, USA), whereas E. coli BL21 (DE3) pLysS (Invitrogen
TM) was used for production of 
recombinant proteins. All strains generated were stored at −80 °C as glycerol stocks (15% glycerol in 
LB-medium). Cultivation of E. coli strains was carried out at 37 °C in LB (lysogeny broth)-medium 
(1% bacto-tryptone; 0.5% yeast extract; 1% NaCl; pH 7.5) containing the appropriate antibiotics 
(E. coli TOP10 strains: 100 µg/mL ampicillin; E. coli BL21 strains: 100 µg/mL ampicillin + 35 µg/mL 
chloramphenicol). Medium was solidified with 1.8% agar agar when needed. 
In order to produce plasmid encoded proteins in E.coli BL21(DE3) pLysS, fresh LB-medium was 
inoculated with pre-grown (LB-media; 37 °C, overnight) cells yielding an OD620 of 0.2. The growth of 
the culture at 30°C was monitored until the OD620 had reached 0.7. At this point IPTG was added up to 
a final concentration of 1 mM. The cultivation was continued for another 3 h before the cells were 
harvested by centrifugation (3,220  g; 10 min), washed (with water and with 0.1 M potassium 
phosphate buffer) and subjected to disintegration. 
3.1.2. Molecular Biology Techniques/Construction of Plasmids 
Cloning and modification of DNA was carried out using standard techniques as described by [68]. 
Plasmids were isolated using the GeneJet MiniPrep Kit from Fermentas. In order to construct an 
E. coli strain capable of Gre2p expression, the GRE2 gene was subcloned from p423-GPD-YOL151w 
(HIS3) [69] into pRSET B (Invitrogen) after introducing the restriction sites PstI and HindIII. The 
resulting plasmid was named pRSET B GRE2.Site-directed mutations were introduced into the gene of 
interest by using an adapted Quikchange
TM protocol. Therefore a 50 µL PCR-reaction contained 0.5 µg 
of template (pRSET B GRE2), 200 µM dNTP’s, 0.18 µM of each primer (Table 4) and 2.5 U Pwo-
Polymerase (Roche). After a 5 min initiation phase at 94 °C to denature template DNA, amplification 
of the desired plasmid was achieved with 18 cycles of the following temperature regime: 94 °C 
(0.5 min); 55 °C (0.5 min); 68 °C (6 min) followed by a final 10 min elongation phase at 68 °C. The 
success of the PCR could be verified by agarose-gel electrophoresis of 15 µL of the product mixture. 
In order to destroy the template 20 µL of PCR product were treated with 1 µL of DpnI FastDigest
TM 
(Fermentas) enzyme for 1 h at 37 °C. Finally 1 µL of the DpnI treated and untreated PCR-reaction-
product, respectively was transformed into electrocompetent E.coli TOP10 cells by electroporation. 
After cultivation on LB-agar overnight 2 colonies were picked for propagation, isolation and 
sequencing of the plasmid if the number of colonies arising form cells transformed with untreated Int. J. Mol. Sci. 2010, 11                 
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PCR-product exceeded the number of colonies arising from cells transformed with DpnI treated   
PCR-product, by a factor of ~10. 
Table 4. Primers used in this study. 
Name
a  Sequence
b 
GRE2N_F (PstI)
c  5’-AACTGCAGAACAGATAGCAGTATCACACGCCCGTAAAT-3’ 
GRE2N_R (HindIII)
c  5’-AAAAGCTTGAAGAGAAAAATGCGCAGAGATGTACTAGATGAT-3’ 
R32E_F  5’-GGTCATCGGTTCTGCCGAAAGTCAAGAAAAGGCCGAGAATTTAACGG-3’ 
R32D_F  5’-GGTCATCGGTTCTGCCGACAGTCAAGAAAAGGCCGAGAATTTAACGG-3’ 
R32G_F (BamHI)  5’-GGTCATCGGTTCTGCCGGATCCCAAGAAAAGGCCGAGAATTTAACGG-3’ 
R32L_F  5’-GGTCATCGGTTCTGCTTTAAGTCAAGAAAAGGCCGAGAATTTAACGC-3’ 
A31E_F  5’-GAAGACTATAAGGTCATCGGTTCTGAGAGAAGTCAAGAAAAGGCC-3’ 
A31D_F (BstYI)  5’-GAAGACTATAAGGTCATCGGATCTGATAGAAGTCAAGAAAAGGCC-3’ 
N9D_F (BsgI)  5’-CAGTTTTTGTTTCAGGTGCAGACGGGTTCATTGCCCAAC-3’ 
N9E_F  5’-CAGTTTTTGTTTCAGGTGCTGAGGGGTTCATTGCCCAAC-3’ 
a   name of the primer is deduced from the amino acids changed in Gre2p; only forward primer 
given; reverse primer corresponds to the reverse complement of the forward primer;  
b  nucleotides in the primer being responsible for amino acid exchange in Gre2p are printed in 
bold face; restriction sites are underlined; c – Primer for introduction of restriction sites (given 
in parenthesis; underlined in sequence) flanking the cloned GRE2 gene. 
3.2. Homology Modeling 
The three-dimensional structural model of Gre2p was constructed through homology modeling 
using the crystal structure of carbonyl reductase from Sporobolomyces salmonicolor (PDB: 1Y1P) as a 
template. In brief a sequence alignment between GRE2 and 1Y1P was generated under due 
consideration of the templates secondary structure with Clustal X2 (profile alignment mode, standard 
parameters) [70]. The alignment was optimized manually by using the software swiss pdb-viewer 
(SPDV) [71] Version 4.0.1, with the “mean force potential” [72] of each amino acids serving as the 
optimization criteria. After removal of clashes in the protein structure by SPDV, the final homology 
model was automatically built by the Swiss Model Server [73]. The latter also allows for assessing the 
quality of the obtained model through different scoring functions such as QMEAN [54] and ProQres 
[53]. All figures showing enzyme structures were generated with SPDV Version 4.0.1 [71]. 
3.2.1. Enzyme Assays 
The activity of Gre2p towards the diketone 2,5-hexanedione was determined by measuring the 
decrease in absorbance of NAD(P)H at 340 nm with a spectrophotometer. If not stated otherwise, the 
standard assay in 0.1 sodium phosphate buffer pH 7.0 contained, the enzyme, 10 mM 2,5-hexanedione 
and 0.2 mM of the reduced cofactor. The reaction was started by addition of 2,5-hexanedione and 
monitored for 90 s. In terms of this assay 1 U corresponds to the formation and consumption, 
respectively of 1 µmol of cofactor per min at pH 7.0 and 30 °C. 
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3.2.2. Disintegration of E. coli Cells 
E. coli cells were disintegrated by adding the non-ionic detergent B-PER (Pierce) in twice the 
amount of the cells wet weight. After addition of DNAse (Promega; 1 U/µL; vDNAse = 1/60 of the 
volume of B-PER) the mixture was shaken for 20 min. The cell crude extract was obtained after 
removing cell debris by centrifugation (10 min; 16,100  g). 
3.2.3. Kinetic Characterization 
Determination of an enzymes apparent Michaelis-constant KM and the apparent maximal velocity 
vmax for the reduction of 2,5-hexanedione was carried out by using 2,5-hexanedione in saturation 
(10 mM) and varying the concentration of the cofactor within the range of 0.1-4 mmol. The constants 
were obtained through fitting the data to the Michaelis-Menten-equation (non-linear regression). 
Before use the recombinant enzyme was enriched from crude extracts of E. coli by treating the crude 
extract with 20% (NH4)2SO4 and removing the precipitate. 
4. Conclusions 
It is widely recognized that biocatalysis is an invaluable tool to produce chiral building blocks and 
other high value chemicals in an economically attractive and environmentally benign way. However in 
order to be applied in an industrially relevant process on a larger scale, biocatalysts often need to be 
tailored to the process requirements. One example is switching the cofactor preference of NADPH 
dependent dehydrogenases to NADH, the latter being more cost-effective and more stable than its 
phosphorylated counterpart. The method of choice to achieve this goal is mutagenesis, as it allows for 
tailoring the enzyme’s properties through either random or rational modification of its primary structure.  
In this study we investigated the impact of rationally introduced mutations upon cofactor preference 
of the NADPH-preferring dehydrogenase Gre2p originating from S. cerevisiae, which proved to be a 
valuable biocatalyst such as the reduction of the diketone 2,5-hexanedione. As the products of this 
reaction [(5S)-hydroxy-2-hexanone and (2S,5S)-hexanediol] are important chiral building-blocks, 
Gre2p is of major economic relevance for industry. However in order to apply this process on an 
industrial scale, an NADH preferring variant of Gre2p would be favorable.  
In theory substitution of one amino acid should suffice to invert cofactor preference. Although this 
has been reported to be true for a series of short-chain-dehydrogenases – an enzyme superfamily 
Gre2p belongs to – the situation appears more complex with this enzyme. However there were two 
promising enzyme variants among the set of mutants generated and tested for activity which lead to a 
relaxation of cofactor preference yielding a mutant which accepts NADPH as well as NADH for the 
reduction of 2,5-hexanedione. The obtained results suggest that the GxxG motif which is often found 
at the N-termini of short-chain dehydrogenases/reductases (SDR), is a promising target in general, if 
the cofactor preference of a SDR is to be altered. As the impact of introduced mutations on enzyme 
activity and selectivity is still not predictable reliably, more structure activity studies on enzymes are 
needed in order to achieve the ultimate goal of de novo design of tailored biocatalysts. Int. J. Mol. Sci. 2010, 11                 
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